AVE5530 + statin

AVE5530 + statin is a **combination therapy** typically referring to the co-administration of AVE5530 (also known as **ezetimibe**, a cholesterol absorption inhibitor) with a **statin** (any member of the HMG-CoA reductase inhibitor class, such as simvastatin, atorvastatin, pravastatin, rosuvastatin, etc.). Ezetimibe inhibits the absorption of cholesterol in the small intestine, while statins reduce cholesterol synthesis in the liver, offering a complementary dual mechanism to lower LDL cholesterol. This combination is used for treating **primary hypercholesterolemia**, **mixed hyperlipidemia**, and certain genetic lipid disorders. It is developed for patients who do not reach lipid goals on statin monotherapy or require additional LDL reduction. Marketed combination products with specific statins exist (e.g., ezetimibe/simvastatin as Vytorin, ezetimibe/atorvastatin as Liptruzet), but "AVE5530 + statin" encompasses the broader category of any pairing of ezetimibe with a statin[1][2][4].